Jun 25, 2019

Video proceedings from the third in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Dr Edward B Garon, Dr Matthew Gubens, Ms Blanca Ledezma and Ms Wendi S Lee.

• Introduction (0m0s)
  • Program overview: Dr Love
• Historical Treatment Paradigms and Related Outcomes for Patients with Stage III Non-Small Cell Lung Cancer (NSCLC); Biologic Rationale for the Evaluation of Immune Checkpoint Inhibitors in This Setting (00:54)
• Case (Ms Lee): A woman in her early 70s with Stage IIIA adenocarcinoma of the lung who received concurrent chemoradiation therapy and developed Grade 2 esophagitis (1:16)
• Available Efficacy Data with and Indications for Durvalumab Consolidation in Unresectable Stage III Disease (16:22)
• Case (Ms Ledezma): A man in his early 70s who received chemoradiation therapy and consolidation durvalumab for new primary Stage III NSCLC after undergoing treatment for Stage IIIB disease 10 years prior (16:34)
• Case (Ms Lee): A woman in her early 70s with Stage IIIB adenocarcinoma of the lung who underwent concurrent chemoradiation therapy followed by durvalumab consolidation (28:59)
• Incidence, Recognition and Management of Immune-Mediated and Other Toxicities Associated with the Use of Durvalumab in Unresectable Stage III Disease (55:03)
• Case (Ms Ledezma): A man in his mid-70s with Stage IIIA NSCLC who enrolled on a clinical trial of neoadjuvant atezolizumab and developed pneumonitis (1:8:31)
• Case (Ms Ledezma): A woman in her early 50s who was found to have a Stage III adenocarcinoma of the lung with an EGFR tumor mutation while undergoing workup for breast cancer and received chemoradiation therapy and durvalumab consolidation (1:13:58)
• Case (Ms Lee): A man in his 50s with Stage IIIA adenocarcinoma of the lung who received chemoradiation therapy and consolidation durvalumab after undergoing lobectomy (1:17:10)

Select publications